Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

Pfiz­er’s Covid sto­ry — and rev­enue spree — con­tin­ue with $54B vac­cine and pill in spot­light again

Covid, Covid and more Covid news and ques­tion­ing dom­i­nat­ed Pfiz­er’s fi­nan­cial call with in­vestors on Tues­day — and of course, its top line rev­enue.

Pfiz­er re­port­ed sales of $25.7 bil­lion for the first three months, dri­ven by $13.2 bil­lion in Comir­naty vac­cine sales and $1.5 bil­lion in Paxlovid an­tivi­ral treat­ments. Over­all, it notched a me­te­oric 77% in­crease year over year — al­though ex­clud­ing Comir­naty and Paxlovid from both quar­ters that drops to 2% op­er­a­tional growth.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.